Skip to main content
Psyence Group Inc. logo

Psyence Group Inc. — Investor Relations & Filings

Ticker · PSYG ISIN · CA74449Q2053 LEI · 549300RPEOIVSD0MJC07 CSE Manufacturing
Open in API
Filings indexed 195 across all filing types
Latest filing 2024-02-28 Interim / Quarterly Rep…
Country CA Canada
Listing CSE PSYG

About Psyence Group Inc.

https://psyence.com/

Psyence Group Inc. is a science-led life science biotechnology company focused on the research, cultivation, and production of natural psychedelics and nature-based compounds. The company develops innovative, safe, and effective solutions for mental health. Its core clinical division, Psyence Therapeutics (now part of Psyence Biomedical Ltd.), pioneers the use of natural psilocybin formulations and treatment protocols, primarily targeting anxiety and depression within the context of palliative care. Supporting this effort, the company operates one of the world's first federally licensed, ISO22000 certified psilocybin cultivation and production facilities. Furthermore, Psyence Function markets a range of non-psychoactive functional mushroom wellness products utilizing adaptogens.

Recent filings

Filing Released Lang Actions
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management Discussion & Analysis (MD&A) for the three months and nine months ended December 31, 2023' and dated February 28, 2024. It contains detailed discussion of operations, financial information, liquidity, risk factors, corporate structure, and forward-looking statements. The text explicitly identifies itself as an MD&A, which is a management report explaining financial results and business trends for a period shorter than a full fiscal year (quarterly and nine months). The document is about 15,000 characters long, indicating it is a substantive report, not a brief announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2024-02-28 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Unaudited Condensed Consolidated Interim Financial Statements For the three and nine months ended December 31, 2023' and contains detailed financial statements including statements of financial position, net profit or loss, changes in equity, cash flows, and notes. It explicitly states it is an interim report prepared under International Accounting Standards 34 – Interim Financial Reporting. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. There is no indication that this is a certification, announcement, or other type of filing. Therefore, this document is a comprehensive interim financial report covering a period shorter than a full fiscal year, fitting the definition of an Interim / Quarterly Report (IR).
2024-02-28 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the completion of a business combination (merger) between Psyence Biomedical Ltd and Newcourt Acquisition Corp, resulting in Psyence Biomedical being listed on the NASDAQ. It discusses the merger approval, the listing, and related financing activities. There are no financial statements, detailed financial performance data, or regulatory filings such as 10-K or interim reports included. The document focuses on the merger event and capital raising through convertible notes. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes related to the merger and financing. The document length is about 10,499 characters, which is substantive and not a mere announcement of a report publication. Therefore, the correct classification is CAP with high confidence.
2024-01-26 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a definitive agreement for a convertible note financing related to a planned business combination involving Psyence Group Inc and Newcourt Acquisition Corp. It details the terms of the note financing, the business combination, and related legal and regulatory information. There are no financial statements or detailed financial performance data presented. The document primarily serves as a capital/financing update and business combination announcement rather than a full financial report or proxy statement. It also references filings like the Form F-4 and proxy statement but does not contain those documents themselves. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-01-16 English
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a press release announcing the resignation of a board member, Mr. Marvin Singer, from Psyence Group Inc. It discusses the board vacancy and the company's commitment to maintaining a strong board. There is no financial data, no mention of annual or quarterly reports, no audit information, no voting results, no capital changes, and no legal proceedings. The content focuses solely on a change in the company's board of directors. Therefore, the document fits the category of Board/Management Information (MANG). The document length is about 5303 characters, which is sufficient for a detailed announcement rather than a brief notice. Hence, the classification is MANG with high confidence.
2023-11-20 English
Other material contracts - English.pdf
M&A Activity Classification · 95% confidence The document is titled 'First Amendment to Amended and Restated Business Combination Agreement' and details specific amendments to an existing business combination agreement involving a SPAC and related entities. It discusses changes to warrant treatment and other contractual provisions. There is no financial data, earnings information, or regulatory certification. The content is a legal amendment to a merger agreement, which falls under merger and acquisition activity filings rather than a full merger proxy statement or tender offer form. Therefore, the document is best classified as related to M&A activity amendments.
2023-11-16 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.